Illumina’s deal to buy cancer test developer blocked by EU

BRUSSELS—The blocked European Union Illuminated acquisition of cancer test developer Grail Inc., jeopardizing a $7.1 billion merger just days after a U.S. administrative judge cleared it to go ahead.

The fate of the acquisition has emerged as a first test for regulators in the United States and the EU who have pledged to take a closer look at mergers after years of allowing numerous corporate combinations.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button